Skip to main navigation Skip to search Skip to main content

FDA Approval of the First-Ever PROTAC: Vepdegestrant (ARV-471) Marks a New Era in Targeted Protein Degradation

  • Anil Kumar
  • , Saghir Ali
  • , Qiang Shen
  • , Jia Zhou

Research output: Contribution to journal › Editorial › peer-review

Original languageEnglish (US)
Pages (from-to)16135-16142
Number of pages8
JournalJournal of medicinal chemistry
Volume69
Issue number14
DOIs
StatePublished - Jul 23 2026

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this